share came pressur like due lower expect op
profit growth maintain despit strong better expect guid
expect off-set out-performance retail howev think weak present
buy opportun focu remain aet share still under-valued
pro-forma basi includ aet
aet acquisit remain track integr plan alreadi underway
expect management provid updat regard pend acquisit aet
approv aet sharehold march notabl state
legal regulatori team made signific progress sinc announc
transact current process respond second request
 depart justic receiv februari file
submit state depart insur januari florida alreadi
provid approv april management re-affirmed expect close acquisit
second-half
integr plan alreadi underway format integr
manag offic imo primari goal imo ensur smooth transit
along lay path expect synergi second full
year oper creat long-term roadmap growth close
transact integr work stream develop focus effici
oper process captur opportun growth innov identifi
compon synergi target second year oper
underli fundament retail pharmaci better expect
reaffirm retail/ltc adj oper profit growth guidanc
low-singl digit despit management lower contribut expect
busi impli underli fundament retail better expect
specif retail/ltc net revenu growth exceed guidanc
total compstore compar guidanc meanwhil
same-stor adj script growth came toward top-end guidanc
adj oper profit growth compar guidanc low-
mid-singl digit result management rais net revenu growth guidanc
compstore guidanc same-stor adj script
guidanc
valuat look even compel current level
due pressur share today like due management revis expect lower
contribut busi think valuat look even compel
pro-forma basi like first full year aet share current
trade updat adj ep estim believ mani
overlook fact consensu adj ep estim reflect
contribut aet even look consensu stand-alon estim share look
attract current trade consensu adj ep
pleas see page report import disclosur
current invest thesi lie acquisit aet view favor
think care coordin combin entiti posit well value-
base care addit share look under-valued current level pro-forma basi
mani may overlook fact consensu estim lack contribut aet
furthermor share even look attract stand-alon basi also see upsid
estim revenu synergi opportun see favor risk/reward
 progress regulatori approv
process pend acquisit aet
 top-lin growth retail/ltc
revenu pbm revenu
 oper margin modestli
y/i due increment oper expens
reinvest mix shift toward
pbm segment
 assum share repo
 strong retail comp better macro
environ coupl better pbm
 stronger gener lower
 sooner expect close aet
debt paydown greater
 slower expect growth
 weaker expect gener
greater expect reimburs
 less expect debt paydown
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
updat estim maintain price target
rais adj ep estim larg due lack
interest expens attribut aet acquisit slightli rais adj ep
estim said maintain price target base
revis dcf analysi impli share trade adj ep
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work termin valuefre pv npv free futur excess valu total number valu per year end decemb cowen
million except per-shar data
compani report cowen compani
interseg good interseg cost good gener amort ex-deal oper expens tax provis tax incom continu incom intang earli extinguish discontinu loss non-controlling financ wtd averag ep cont chang year end decemb cowen
million except per-shar data
compani report cowen compani
interseg good interseg cost good gener amort ex-deal oper expens tax provis tax incom continu incom alloc particip intang earli extinguish discontinu loss non-controlling financ wtd averag ep cont chang cowen
million
compani report cowen compani
asset cash receiv incom current equip asset liabil account discount portion long-term current incom non-curr non-controlling equiti common held comprehens sharehold sharehold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end decemb cowen
million
compani report cowen compani
income/ loss flow oper activ depreci stock-bas loss earli extinguish debt- sale subsidiary- defer incom tax non-cash chang oper asset liabil account receiv current account accru long-term net cash oper acquisit properti acquisit issuance/ repurchas common purchas treasuri stock- dividend proceeds/ purchas secur proceeds/ repay debt other- net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end decemb cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net earn net cash depreci goodwil impairment- loss settlement defin benefit pension plans- stock-bas loss earli extinguish debt- sale subsidiary- defer incom tax non-cash chang oper asset liabil account receiv current account accru long-term net cash provid oper flow invest activitiespurchas properti proce sale-lease-back proce sale properti acquisit net cash acquir purchas available-for-sal sale short-term investments- sale matur available-for-sal proce sale subsidiary- proce sale dispos assets- net cash use invest flow financ activitiesincreas decreas short-term repay debt assum acquisition- proce issuanc long-term repay long-term debt- purchas non-controlling interest subsidiary- dividend deriv settlements- proce exercis stock excess tax benefit stock-bas repurchas common net cash provid use financ effect exchang rate cash- net decreas cash cash cash equival begin cash equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
lack regulatori approv acquisit aet challeng
later expect roll-on contract
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
